Login
Companies $AUPH
$15.45 -$0.03 (0.19%) After hours
Aurinia Pharmaceuticals Inc. logo

Aurinia Pharmaceuticals Inc.

auriniapharma.com

What Do They Do?

Sells LUPKYNIS, an oral treatment for adults with active lupus nephritis, to specialty pharmacies, a specialty distributor and a pharmaceutical partner, and develops aritinercept for autoimmune diseases.

How Do They Make Money?

Aurinia sells LUPKYNIS to specialty pharmacies, a distributor and Otsuka; product sales are paid after delivery under standard customer credit terms. Its Otsuka deal also brings an upfront license fee, milestone payments, royalties as partner sales occur, and payment for product supply and manufacturing services.

revenue
SegmentShareRevenue
Net product sales
Sold outright

96%
FY2022: 77%
License, collaboration and royalty revenue
4.1%
FY2022: 23%

Who Are Their Customers?

Aurinia sells LUPKYNIS to U.S. specialty pharmacies and a specialty distributor; Otsuka buys inventory for European and Japanese markets, where it markets the drug.

Do Revenues Turn Into Profits?

Yes. Its net income in FY2025 was larger than its revenue and turned 48 cents into free cash flow.

Operating income, FY2025
37% of revenue
▲ Turned profitable vs FY2024 (−$4.7M, −2%)
Net income, FY2025
101% of revenue
▲ +4893% vs FY2024 ($5.8M, 2%)
Free cash flow, FY2025
48% of revenue
▲ +207% vs FY2024 ($44.1M, 19%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +14%
vs $73.5M in Q3 FY2025
Net income
▲ 0%
vs $31.6M in Q3 FY2025
Net product sales share of revenue vs 96.1% in Q3 FY2025
  • Aug 6, 2026 Reiterated annual revenue and product-sales guidance Aurinia maintained its revenue and net product-sales ranges for the year.
  • May 11, 2026 Completed acquisition of Kezar Life Sciences The tender offer and merger closed, leaving Kezar as Aurinia's wholly owned subsidiary.
  • Apr 3, 2026 Agreed to acquire Kezar Life Sciences The agreement set out a tender offer and merger, subject to closing conditions.
  • Mar 23, 2026 CEO and CFO departures followed by appointments Kevin Tang became CEO; Michael Hearne became CFO, and Peter Greenleaf and Joseph Miller left their officer roles.

Growing. Revenue grew 6.2x in 4 years, from $45.6M in FY2021 to $283.1M in FY2025, about 58% a year.

Narrower stated disease focus The older report described a broader focus spanning autoimmune, kidney and rare diseases; the latest describes LUPKYNIS for lupus nephritis and aritinercept for autoimmune diseases.

Revenue over time
Net product sales License, collaboration and royalty revenue
$500M$250M$0

Who Do They Compete With?

Competes with GSK and Genentech

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support